Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

MEN-10755. Menarini.

¹University of Texas MD Anderson Cancer Center, Department of Pharmacy, 1515 Holcombe Boulevard, Houston, TX 77030, USA. kljones@mdanderson.org

Current Opinion in Investigational Drugs (London, England : 2000)

|February 7, 2004

Summary

This summary is machine-generated.

Menarini is investigating MEN-10755, an anthracycline aminodisaccharide, for solid tumor treatment. Phase II trials are assessing its efficacy across various cancers, including lung, breast, and ovarian tumors.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis-Related Diabetes.

Journal of investigative medicine high impact case reports·2019

Same author

The impact of continuous positive airway pressure on radiation dose to heart and lung during left-sided postmastectomy radiotherapy when deep inspiration breath hold technique is not applicable: a case report.

Radiation oncology journal·2018

Same author

Metastatic Lung Carcinoma Involving the Maxillary Gingiva.

The Journal of the Oklahoma State Medical Association·2016

Same author

Review and Outcome of Prolonged Cardiopulmonary Resuscitation.

Critical care research and practice·2016

Same author

STOP-BANG questionnaire as a screening tool for diagnosis of obstructive sleep apnea by unattended portable monitoring sleep study.

SpringerPlus·2015

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Area of Science:

Oncology
Pharmacology

Background:

Menarini is developing MEN-10755, a novel anthracycline aminodisaccharide.
This compound shows potential for treating various solid tumors.

Purpose of the Study:

To evaluate the therapeutic activity of MEN-10755.
To assess the drug's efficacy in patients with sarcoma, ovarian, breast, prostate, and lung cancers.

Main Methods:

Six Phase II clinical trials were initiated in 2000.
Trials focus on verifying the anticancer effects of MEN-10755.

Main Results:

Data from Phase II trials are pending or under analysis.
Efficacy and safety profiles are being determined for specific tumor types.

Conclusions:

The ongoing trials will determine the clinical utility of MEN-10755.
Results will inform potential future development for solid tumor treatment.